Pharmaids Pharmaceuticals share news, announcements and annual reports
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Pharmaids Pharmaceuticals Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994
Last close ₹27.72down ₹0.70 (2.46%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹28.42.
30 Oct: open ₹28.00, high ₹28.89, low ₹27.50
52-week range of traded prices to 30 Oct 2026
₹25.60Low, 1 Jun 2026₹53.90High, 9 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹98 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,285
Pharmaids Pharmaceuticals board and management
41 filed, newest first.
Jun 2026
Jan 2026
Dec 2025
10 Dec · Management
Nov 2025
Sep 2025
Aug 2025
21 Aug · Management
Jul 2025
4 Jul · Management
Mar 2025
Feb 2025
Aug 2024
May 2024
Feb 2024
Jan 2024
Aug 2023
Jan 2023
Oct 2022
Aug 2022
Jan 2021
Feb 2020
Jun 2019
Nov 2018
13 Nov · Management
Aug 2018
13 Aug · Management
Feb 2018
15 Feb · Management
Aug 2017
21 Aug · Management
May 2015
29 May · Management
Mar 2015
31 Mar · Management
Smt. Seema Jain has been appointed as an additional director of the Company with effect from March 30, 2015.
May 2014
30 May · Management
May 2013
31 May · Management
Dec 2012
10 Dec · Management
Mr. Hasmuk Lalwani S/o. Sri Babutmal Lalwani, has resigned as Director of the Company in the 2nd quarter Board of Directors Meeting held ....